Hormonal Therapy of Breast Cancer: New Approaches and Concepts

  1. SEWA S. LEGHA, M.D., F.A.C.P.;
  2. HUGH L. DAVIS, M.D.; and
  3. FRANCO M. MUGGIA, M.D., F.A.C.P.

    Abstract

    The most useful new hormonal therapy against estrogen receptor-containing metastatic breast cancer is the development of antiestrogenic agents such as nafoxidine and tamoxifen. Both of these drugs possess antitumor activity comparable to that of other additive hormonal agents, and they are better tolerated for lack of any serious toxicity. The clinical usefulness of antiprolactin drugs in breast cancer is at present limited. Adrenal suppression using aminoglutethimide has been shown to induce useful remissions. We discuss the implications of new treatment modalities for the future management of disseminated breast cancer.

    Article and Author Information

    • ▸From the Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute; Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to Sewa S. Legha, M.D.; Department of Developmental Therapeutics, M. D. Anderson Hospital, 6723 Bertner; Houston, TX 77030.

      • Received January 4, 1977.
      • Accepted May 24, 1977.
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med January 1, 1978 vol. 88 no. 1 69-77
    1. » Abstract
    2. Full Text (PDF)
    3. References

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. February 2, 2010, 152 (3)
    1. Alert me to current issues